Loading
A phase 1/2 trial of BI-1607 run by BioInvent International AB, terminated.
BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05555251 by BioInvent International AB, with 18 participants enrolled, started 2022-07-28. Conditions recorded: HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma and Metastatic Gastric Adenocarcinoma. Interventions recorded: BI-1607, BI-1607 and Trastuzumab.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares HER2-positive gastric cancer, HER2-positive breast cancer and the tag pipeline.
Shares HER2-positive gastric cancer, HER2-positive breast cancer and the tag pipeline.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares BioInvent International and the tag pipeline.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/